With a robust economy, Israeli pharma market set to reach $2.12 billion by 2020

2 December 2016
globaldata-logo-big

The Israeli pharmaceutical market is set to rise from a value of $1.75 billion in 2015 to around $2.12 billion by 2020, representing a compound annual growth rate of 3.9%.

Research and consulting firm GlobalData’s latest report states that medical technological advances and R&D expenditure in the field of science and technology are distinguishing features of the Israeli pharmaceutical market. Indeed, the pharmaceutical space is supported by a network of recognized academic and research institutes, R&D facilities, and well-developed medical centers. Israeli research expertise and clinical advances have led to the development of blockbuster drugs and promising treatments for cancer, multiple sclerosis and Alzheimer’s disease.

Despite armed conflict with neighboring Arab countries and large-scale immigration, which has placed a heavy burden on the economy, Israel is a developed, industrialized country with a small, technologically-advanced agricultural sector, a growing service sector and a substantial high-tech sector. In this way, the economy is fairly robust and presents ample opportunity for a thriving pharmaceutical sector.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical